Abbott acquisition of Alere set to close on October 3, 2017

Press releases may be edited for formatting or style | October 02, 2017 Cardiology

WALTHAM, Mass., Sept. 29, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) announced today that Abbott's acquisition of Alere is intended to close on October 3, 2017. The announcement follows receipt of all regulatory clearances necessary for closing.

Alere intends to request that the New York Stock Exchange cease trading of Alere's common stock before market open on October 3, 2017.

About Alere

You don’t have to invest heavily in CT technology to achieve your Coronary CTA goals

Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.

Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™. Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology.

SOURCE Alere Inc.



You Must Be Logged In To Post A Comment Sign In If you've already created an account, use your email address and password to sign in using the form below. Login Problems: Click here if you are having login issues. Email address: Password: Forgot your password? Login Problems? View our Legal Notice and Privacy Notice Register Registration is Free and Easy. Enjoy the benefits of The World's Leading New & Used Medical Equipment Marketplace. Register Now!